HLS — HLS Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$151.46m
- CA$241.32m
- $63.07m
- 54
- 68
- 44
- 56
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | Interim Report | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 54.2 | 56.1 | 60 | 61.5 | 63.1 |
Cost of Revenue | |||||
Gross Profit | 52.2 | 52.5 | 56 | 56.5 | 55.5 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 74.6 | 72.9 | 71.8 | 85.2 | 90.9 |
Operating Profit | -20.5 | -16.8 | -11.8 | -23.7 | -27.8 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.5 | -16.3 | -11.8 | -23.7 | -27.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.6 | -15.3 | -13.1 | -23.6 | -27.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -19.6 | -15.3 | -13.1 | -23.6 | -27.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.6 | -15.3 | -13.1 | -23.6 | -27.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.645 | -0.469 | -0.404 | -0.624 | -0.728 |
Dividends per Share |